DALLAS, Sept. 21, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Cell Therapeutics Inc. (Nasdaq:CTIC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at:
Cell Therapeutics Inc. (CTIC) develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. The Company is focused on developing pixantrone, OPAXIO, brostallicin and bisplantinates. Pixantrone is an anthracycline derivative for the treatment of non-Hodgkin's lymphoma (NHL) and various other hematologic malignancies, solid tumors and immunological disorders. The Company is developing OPAXIO (paclitaxel poliglumex), a maintenance therapy for women with advanced stage ovarian cancer. Brostallicin is a synthetic Deoxyribonucleic Acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity. In March 2009, the Company sold its 50% interest in RIT Oncology.
Message Board Search for CTIC:
In the report, the analyst notes:
"For the quarter ended June 30, 2010, total net operating expenses were $20.0 million compared to $21.7 million for the same period in 2009. Net loss attributable to common shareholders was $53.6 million ($0.08 per share) for the quarter ended June 30, 2010, compared to a net loss attributable to common shareholders of $27.4 million ($0.06 per share) for the same period in 2009.
"CTIC recently announced that it intends to appeal the U.S. Food and Drug Administration's (the "FDA") previously disclosed decision regarding the pixantrone New Drug Application ("NDA") to treat patients with relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL"). CTIC had requested accelerated approval of its NDA for this patient group for which there are no currently approved drugs."
To read the entire report visit:
See what investors are saying about CTIC at
Get breaking news on CTIC at
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit:
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
CONTACT: MicroStockProfit.com Brian Johnson email@example.com 1-888-307-2850